Drug intelligence / Profile preview

bevacizumab + nivolumab + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination of three drugs: bevacizumab (an anti-VEGF monoclonal antibody), nivolumab (a PD-1 inhibitor), and pembrolizumab (another PD-1 inhibitor). While not typically used together as a triple combination in standard practice, the individual drugs or dual combinations have shown synergistic effects in cancer treatment. Bevacizumab works by inhibiting angiogenesis through VEGF blockade, while nivolumab and pembrolizumab are both immune checkpoint inhibitors that target PD-1 to enhance T-cell immune response against cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + nivolumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + nivolumab + pembrolizumab.

Explore the full profile